Summary
Amonafide, a synthetic benzisoquinolinedione, was evaluated for treatment of squamous esophageal cancer. Eleven men and 5 women were eligible with a median performance status of 1 and median age of 63 years. Six had no prior treatment. All patients had measurable disease. Therapy consisted of amonafide 300 mg/m2d days 1–5 every 21 days. Thirty-five courses of therapy were delivered. The median number of courses received was two. Sixteen patients are evaluable for toxicity. Thirteen are evaluable for response. Toxicity was severe. Seven patients were hospitalized for toxicity. Six patients had grade IV granulocytopenia; two, grade IV thrombocytopenia. Angioedema developed in one patient; severe exfoliative dermatitis in another. A single partial response, with the decrease in size a supraclavicular node, was noted in a previously untreated patient. Amonafide, in this dose and schedule, is associated with occasionally severe toxicity precluding its likely use in squamous cell esophageal carcinoma.
Similar content being viewed by others
References
Brana MF, Castellano JM, Roldan CM, Santos A, Vasquez D, Jimenez A: Synthesis and modes(s) of action of a new series of imide derivatives of 3-nitro-1, 8-napthalic acid. Cancer Chemother Phar 4:61–66, 1980
Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA:In vitro toxicity and DNA cleavage capacity of benzisoquinolinedione (Nafidemide: NSC 308847) in human leukemia. Cancer Res 47:1040–1044, 1987
Clinical Brochure. Benzisoquinolinedione NSC 308847, Bethesda, MD. National Cancer Institute.
Legha S, Ring S, Raber M, Felder T, Newman R, Krakoff I: Phase I clinical investigation of benzisoquinolinedione. CTR 71:1165–1169, 1987
Puccio D, Mittelman A, Ahmed T, Coombs N, Feldman E, Nadler P, Kreis W, Molt P, Chun H, Arlin Z: Phase I trial and pharmacokinetics of amonafide. Proc ASCO 10:A316, 1991
Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, Sarosy G, Von Hoff DD: Phase I clinical investigation of amonafide. Journal of Clinical Oncology 7:1351, 1989
Allen SL, Ratain M, Korzun AH, Duggan D, Nowak B, Norton L, Henderson IC: Phase II study of amonafide in previously treated metastatic breast cancer. Proc AACR 32:A1092, 1991
Scheithauer W, Dittrich C, Kornek G, Linkesch. W, Haider K, Depisch D: A phase II trial of amonafide in metastatic breast cancer. Proc ASCO 10:A138, 1991
Shevrin D, Khandekar J, Kilton L, Holder L, Showel J, Blough R, Watkins A: Amonafide in advanced hormone resistant prostate cancer: An Illinois cancer council phase II study. Proc ASCO 10:A584, 1991
Craig J, Crawford E: Phase II trial of advanced prostate cancer: A southwest oncology group study. Proc ASCO 8:A573, 1989
Evans WK, Eishenhauer EA, Cormier Y, Ayoub J, Wierzbicki R, Labeige F, Shepard FA: Phase II study of amonafide: Results of treatment and lessons from the study of an investigational agent in previously untreated patients with extensive small cell lung cancer. J Clin Oncology 8: 309–395, 1990
Burger MZ, Kris MG, Gralla RJ, Marks LD, Potanovich LM, DiMaggio J J, Heelan RT: Phase II trial of amonafide in patients with stage III and IV non-small cell lung cancer. Am J Clin Onc 14:124–126, 1991
Linke K, Pazdur R, Ajani J, Abbruzzese J, Patt Y, Daugherty K, Levin B: Phase II trial of amonafide in advanced pancreatic carcinoma. Proc ASCO 10:A452, 1991
Slavik M, Kopecky K, Craig J, Sondak V, Samson M: Evaluation of amonafide in disseminated malignant melanom: A southwest oncology group study. Proc ASCO 10:A1022, 1991
Higano CS, Craig J, Goodman P, Blumenstein B, Wettlaufer J, Crawford ED: A phase II trial of amonafide in advanced renal cell carcinoma. Proc ASCO 8:574, 1989
Felder TB, McClean MA, Vestal ML, Luk K, Farquhar D, Legha S, Shar R, Newman RA. Pharmacokinetics and metabolism of the antitumor drug amonafide NSC 308847 in humans, drug metabolism and disposition 15:773–778, 1987
Ratain MJ, Mick R, Berezin F, Janisch L, Shilsky RL, Williams SF, Smiddy J: Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clinical Pharmacology and Therapeutics 50:573–579, 1991
Grever MR, Staubus AE, Malspeis L: Correlation of Nacetylation phenotype with plasma levels of the N-acetyl- metabolite of amonafide (NSC 308847). Proc AACR 31: A1055, 1990
Hochster H, Oratz R, Wernz J, Speyer J, Meyers M, Chachoua A, Walsh C, Dunleavy S, Blum R, Kreis W, Nadler P, Spigelman MK: Weekly amonafide: Phase I study of a novel schedule. Proc ASCO 9:265, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poplin, E., Fleming, T., MacDonald, J.S. et al. Amonafide treatment of refractory esophageal cancer. Invest New Drugs 11, 47–51 (1993). https://doi.org/10.1007/BF00873910
Issue Date:
DOI: https://doi.org/10.1007/BF00873910